Latest Us Market News

ARB Corporation Limited reported a 5.3% increase in FY25 sales revenue to A$729.9 million, driven by strong export growth and strategic US market moves, despite a 5% dip in profit after tax.

Eclipse Metals announces plans for a NASDAQ dual listing to boost its rare earth elements strategy and tap into North American capital markets, while maintaining its ASX presence.

Compumedics has secured a $2.15 million placement to fast-track commercialisation of its Somfit D device following early FDA approval, positioning the company for significant growth in the US home sleep testing market.

Clarity Pharmaceuticals’ Co-PSMA Phase II trial shows its Cu-SAR-bisPSMA diagnostic agent detects more prostate cancer lesions than current standard imaging, promising earlier and more accurate recurrence detection.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

Tungsten Mining NL (ASX, TGN) reinforces its position as a leading tungsten resource holder outside China, unveiling a robust development strategy aligned with soaring global demand and supply constraints.

Pacific Edge reports a 9% decline in Cxbladder test volumes amid Medicare coverage loss but gains momentum with new clinical validation and a CMS pricing boost.

Magnum Mining & Exploration has raised $7 million through an oversubscribed placement to accelerate its critical minerals processing hub in Nevada and expand rare earth exploration in Brazil, aligning with US strategic priorities.

Immuron Limited reports a robust 34% year-on-year sales increase for Q1 FY26, driven by strong growth in Australia and the USA, while Canadian sales dip seasonally. The company’s marketing efforts and expanding retail presence underpin this momentum.

PainChek Limited has secured its first US customer, Jewish Home Family, just days after receiving FDA De Novo clearance for its AI-powered pain assessment app, marking a significant step into the $100 million US aged care market.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

PainChek Limited has achieved a landmark FDA De Novo classification for its PainChek Adult App, positioning it as the first regulated medical device for pain assessment in the US aged care sector and opening a $100 million annual market opportunity.